Antibody-drug conjugate (ADC) therapy is a proven, revolutionary approach designed to target specific tumor cells with high precision while minimizing toxicity to healthy cells.  Good ADC therapy development decisions start with dependable research, and in the challenging, competitive pharmaceutical market, that means accurate, reliable testing protocols and results.  Adopting a robust, sensitive, and specific biomarker assay alongside ADC therapy development is the key to success.